Decitabine Injection

DRUG5 trials

Sponsors

Janssen Korea, Ltd., Korea, Cttq, Fudan University, Children's Hospital of Soochow University, BGI, China

Conditions

AMLAML, ChildhoodC-KIT MutationCore Binding Factor Acute Myeloid LeukemiaMyelodysplastic SyndromeMyelodysplastic SyndromesNeoantigenPFS

Early Phase 1

Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

Enrolling by invitationNCT06499025

BGI, ChinaAML, Neoantigen, t(8;21)

Start: 2024-02-01End: 2027-12-30Target: 16Updated: 2025-08-28

Phase 2

Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

Fudan UniversityPFS

Start: 2023-01-01End: 2024-12-31Target: 60Updated: 2022-12-06

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

RecruitingNCT06316960

Children's Hospital of Soochow UniversityAML, Childhood, C-KIT Mutation, Core Binding Factor Acute Myeloid Leukemia +2

Start: 2024-03-01End: 2027-03-31Target: 50Updated: 2024-08-22

Phase 4

A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome

CttqMyelodysplastic Syndrome

Start: 2013-03-31End: 2015-12-31Target: 240Updated: 2013-12-17

Unknown Phase

An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome

CompletedNCT01400633

Janssen Korea, Ltd., KoreaMyelodysplastic Syndromes

Start: 2010-12-31End: 2014-03-31Updated: 2015-05-25

Related Papers

Adoptive T-cell therapy targeting a novel non-canonical neoantigen derived from a translated AML1-ETO lncrna shows clinical activity in a first-in-human trial for t(8;21) AML

Blood2025-11-03

Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System.

2019-06-273 citations

FINAL Results of an Phase, Multicenter, Randomied, Controlled OPEN LEVEL Trial: Decitabine Therapy in Patients with Myelodysplastic Syndromes

Blood2018-11-291 citations